Short Interest in CytoDyn Inc. (OTCMKTS:CYDY) Expands By 13.5%

CytoDyn Inc. (OTCMKTS:CYDY) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 8,024,100 shares, a growth of 13.5% from the June 30th total of 7,070,900 shares. Based on an average daily trading volume, of 3,704,000 shares, the short-interest ratio is presently 2.2 days.

CytoDyn Stock Up 1.3 %

Shares of CYDY traded up $0.00 during mid-day trading on Wednesday, reaching $0.14. 921,458 shares of the stock traded hands, compared to its average volume of 1,640,773. CytoDyn has a 12-month low of $0.13 and a 12-month high of $0.42. The firm has a market cap of $152.49 million, a price-to-earnings ratio of -2.87 and a beta of 0.14. The stock has a fifty day simple moving average of $0.16 and a 200 day simple moving average of $0.16.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.